Cholesterol emboli syndrome causes: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(One intermediate revision by one other user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Cholesterol emboli syndrome}}
{{Cholesterol emboli syndrome}}
{{CMG}}
{{CMG}} {{AE}}{{NN}}
 
==Overview==
==Overview==
Common causes of [[Cholesterol emboli syndrome]] (CES) include spontaneously due to [[atherosclerosis]] of the large [[arteries]] and iatrogenic secondary to medical interventions such as [[vascular surgery]] or [[angiography]]. Less common causes of CES include intake of [[anticoagulant]]s such as [[warfarin]] or [[thrombolysis|thrombolytic]] medications.
==Causes==
==Causes==
It is relatively unusual (25%) for cholesterol emboli to occur spontaneously; this usually happens in people with severe [[atherosclerosis]] of the large arteries such as the [[aorta]]. In the other 75% it is a complication of medical procedures involving the blood vessels, such as [[vascular surgery]] or [[angiography]]. In [[coronary catheterization]], for instance, the incidence is 1.4%.<ref name=Fukumoto>{{cite journal |author=Fukumoto Y, Tsutsui H, Tsuchihashi M, Masumoto A, Takeshita A |title=The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study |journal=J. Am. Coll. Cardiol. |volume=42 |issue=2 |pages=211–6 |year=2003 |month=July |pmid=12875753 |doi=10.1016/S0735-1097(03)00579-5 | url=http://linkinghub.elsevier.com/retrieve/pii/S0735109703005795}}</ref> Furthermore, cholesterol embolism may develop after the commencement of [[anticoagulant]]s or [[thrombolysis|thrombolytic]] medication that decrease blood clotting or dissolve blood clots, respectively. They probably lead to cholesterol emboli by removing blood clots that cover up a damaged atherosclerotic plaque; cholesterol-rich debris can then enter the bloodsteam.<ref name=Modi/>
*Common causes of [[Cholesterol emboli syndrome]] (CES) include:
**spontaneously (25%): It usually occurs in patients with severe [[atherosclerosis]] of the large [[arteries]] such as [[aorta]].  
**Iatrogenic (75%): a complication of medical procedures involving the blood vessels, such as [[vascular surgery]] or [[angiography]].  
***The incidence of CES after [[coronary catheterization]] is 1.4%. <ref name="FukumotoTsutsui2003">{{cite journal|last1=Fukumoto|first1=Yoshihiro|last2=Tsutsui|first2=Hiroyuki|last3=Tsuchihashi|first3=Miyuki|last4=Masumoto|first4=Akihiro|last5=Takeshita|first5=Akira|title=The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study|journal=Journal of the American College of Cardiology|volume=42|issue=2|year=2003|pages=211–216|issn=07351097|doi=10.1016/S0735-1097(03)00579-5}}</ref>
***But the overall prevalence of CES after [[coronary catheterization]] is 25% to 30%. <ref name="Ramirez1978">{{cite journal|last1=Ramirez|first1=German|title=Cholesterol Embolization|journal=Archives of Internal Medicine|volume=138|issue=9|year=1978|pages=1430|issn=0003-9926|doi=10.1001/archinte.1978.03630340096035}}</ref>
*less Common causes of [[Cholesterol emboli syndrome]] (CES) include:
** intake of [[anticoagulant]]s such as [[warfarin]] or [[thrombolysis|thrombolytic]] medications such as [[tissue plasminogen activator]]that decrease blood clotting or dissolve blood clots, respectively. They probably lead to [[cholesterol emboli]] by removing blood clots that cover up a damaged [[atherosclerotic]] plaque; cholesterol-rich debris can then enter the [[bloodsteam]]. <ref name="Feder1961">{{cite journal|last1=Feder|first1=Walter|title="Purple Toes": an Uncommon Sequela of Oral Coumarin Drug Therapy|journal=Annals of Internal Medicine|volume=55|issue=6|year=1961|pages=911|issn=0003-4819|doi=10.7326/0003-4819-55-6-911}}</ref> <ref name="pmid2507919">{{cite journal| author=Shapiro LS| title=Cholesterol embolization after treatment with tissue plasminogen activator. | journal=N Engl J Med | year= 1989 | volume= 321 | issue= 18 | pages= 1270 | pmid=2507919 | doi=10.1056/NEJM198911023211816 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2507919  }} </ref>


Findings on general investigations (such as [[blood test]]s) are not specific for cholesterol embolism, which makes diagnosis difficult. The main problem is the distinction between cholesterol embolism and [[vasculitis]] (inflammation of the small blood vessels), which may cause very similar symptoms - especially the skin findings and the kidney dysfunction.<ref name=Modi/> Worsening kidney function after an angiogram may also be attributed to kidney damage by substances used during the procedure ([[Radiocontrast#Contrast-induced nephropathy|contrast nephropathy]]). Other causes that may lead to similar symptoms include [[acute tubular necrosis|ischemic renal failure]] (kidney dysfunction due to an interrupted blood supply), a group of diseases known as [[microangiopathic hemolytic anemia|thrombotic microangiopathies]] and [[endocarditis]] (infection of the [[heart valve]]s with small clumps of infected tissue embolizing through the body).<ref name=Modi/>


==References==
==References==
Line 15: Line 23:
[[Category:Vascular surgery]]
[[Category:Vascular surgery]]
[[Category:Disease]]
[[Category:Disease]]
 
[[Category:needs English]]
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Latest revision as of 20:16, 31 January 2021

Cholesterol emboli syndrome Microchapters

Home

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Cholesterol emboli syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cholesterol emboli syndrome causes On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cholesterol emboli syndrome causes

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cholesterol emboli syndrome causes

CDC on Cholesterol emboli syndrome causes

Cholesterol emboli syndrome causes in the news

Blogs on Cholesterol emboli syndrome causes

Directions to Hospitals Treating Cholesterol emboli syndrome

Risk calculators and risk factors for Cholesterol emboli syndrome causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nasrin Nikravangolsefid, MD-MPH [2]

Overview

Common causes of Cholesterol emboli syndrome (CES) include spontaneously due to atherosclerosis of the large arteries and iatrogenic secondary to medical interventions such as vascular surgery or angiography. Less common causes of CES include intake of anticoagulants such as warfarin or thrombolytic medications.

Causes


References

  1. Fukumoto, Yoshihiro; Tsutsui, Hiroyuki; Tsuchihashi, Miyuki; Masumoto, Akihiro; Takeshita, Akira (2003). "The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study". Journal of the American College of Cardiology. 42 (2): 211–216. doi:10.1016/S0735-1097(03)00579-5. ISSN 0735-1097.
  2. Ramirez, German (1978). "Cholesterol Embolization". Archives of Internal Medicine. 138 (9): 1430. doi:10.1001/archinte.1978.03630340096035. ISSN 0003-9926.
  3. Feder, Walter (1961). ""Purple Toes": an Uncommon Sequela of Oral Coumarin Drug Therapy". Annals of Internal Medicine. 55 (6): 911. doi:10.7326/0003-4819-55-6-911. ISSN 0003-4819.
  4. Shapiro LS (1989). "Cholesterol embolization after treatment with tissue plasminogen activator". N Engl J Med. 321 (18): 1270. doi:10.1056/NEJM198911023211816. PMID 2507919.

Template:WikiDoc Sources